25 feb: Indberetningspligtiges handler med Møns Bank A/S aktier
25 feb: Årsrapport 2018
25-02-2019 10:11:37

Coloplast awarded general urological products agreement with Premier Inc.

Coloplast, a global medical device company and leader in intimate healthcare needs, has been awarded a three-year group purchasing agreement for general urological products with Premier. The new agreement allows Premier members access to Coloplast’s full portfolio of general urological products, including catheters, drainage systems and accessories.

“We are extremely honored that Premier Inc. has chosen to work with Coloplast. Coloplast shares Premier’s core values to improve patient outcomes and provide value to its customers,” said Manu Varma, senior vice president of Chronic Care North America.

The agreement is effective for three years beginning March 1, 2019. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Coloplast continence care products

Coloplast’s range of innovative continence care products are created to allow users to better control their bladder management. By working closely with clinical experts and patients who use catheters daily, we have developed award-winning products. This includes SpeediCath®, the world’s first ready-to-use hydrophilic-coated intermittent catheter, and Conveen® Optima, the next generation of male external catheters. These products are designed to improve the quality of life for those in need and are preferred by users.

In addition to product solutions, Coloplast has developed Coloplast® Care, a patient support program which provides catheter users access to education and tools for self-assessment and individualized live support from Care Advisors. Coloplast Care provides reliable information so catheter users can better manage their care and experience a full life.

About Coloplast

Danish medical device company Coloplast develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to end-users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions. www.coloplast.us/about-coloplast

Global press contact

Lina Danstrup, Senior Media Relations Manager

+45 4911 2607

dklina@coloplast.com  

Attachment

logo.png

Relateret indhold
17 apr - 
Onsdagens aktier: Coloplast faldt, men GN faldt mest
17 apr - 
FDA-påbud skærer 25 mio. dollar af toplinjen hos Colopl..
17 apr - 
Middag: Coloplast sætter sig mere end markedet efter FD..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Episode 15 - Lars Seier Christensen ser FC Porto som model for FCK

11-04-2019 15:15:13
I denne episode er finansmanden Lars Seier Christensen gæst i studiet hos Euroinvestors Lars Christensen til en snak om investeringer i sports- og fritidsindustrien med afsæt i Lars Seier Christensens nylige investering i Parken Sport & Entertainment - virksomheden bag fodboldklubben FC København.I samtalen fremhæver Lars Seier Christensen blandt andet den portugisiske fodklub FC Porto som en mode..

Aktier/tendens: Panalpina-tal kan give DSV-fokus i rolig handelsstart

17-04-2019 07:48:02
DSV kan komme i fokus onsdag, efter at schweiziske Panalpina, som den danske transportgigant er ved at overtage, fra morgenstunden har præsenteret regnskabstal, der var bedre end ventet blandt analytikerne.I årets første kvartal nåede Panalpina en omsætning på 1,49 mia. schweizerfranc, svarende til 9,8 mia. kr., hvor der blandt analytikere adspurgt af Bloomberg News var ventet en omsætning på 1,45..

Genmab-partner leverer bedre end ventet: Darzalex skuffer lidt

16-04-2019 12:58:48
Den amerikanske medicinalvirksomhed Johnson & Johnson, der samarbejder med danske Genmab omkring salg af kræftmidlet Darzalex, har leveret et bedre end ventet regnskab for første kvartal.Til gengæld ser det globale salg af Darzalex ud til at skuffe, da det i første kvartal endte på 629 mio. dollar. Til sammenligning havde Sydbanks senioranalytiker Søren Løntoft Hansen ventet et globalt salg på 660..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 685,40 -1,7% Fald i aktiekurs
Coloplast 108,95 0,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. april 2019 20:22:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB7 - 2019-04-19 20:22:32 - 2019-04-19 20:22:32 - 1 - Website: OKAY